Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML who have no satisfactory alternative treatment options, ...

Kyowa Kirin International (KKI) takes highlighting awareness of rare disease X-linked hypophosphatemia (XLH) literally with its immersive virtual exhibition, the “Shine a Light on XLH” campaign. The ...

With an upfront payment of $100 million, Kyowa Kirin has bought into a partnership with BridgeBio to develop and commercialize Truseltiq (infigratinib) in Japan. Besides the sizable upfront ...

Add Yahoo as a preferred source to see more of our stories on Google. A rendering of Kyowa Kirin's new biologics manufacturing facility in Sanford, North Carolina. The $530 million facility will ...

Assuming the transformation of production procedure,Kyowa Leather Cloth set the gaze to Indian market.

Kyowa Kirin (TSE:4151) shares have seen a slight uptick recently, drawing some attention as investors weigh its current position following recent trading activity. The company’s fundamentals and ...

Kyowa Kirin is expanding its scope to genetic medicines by acquiring Orchard Therapeutics, a company whose gene therapy for a rare inherited metabolic disorder is commercialized in Europe and is on ...

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson's disease candidate KW-6356, a drug in the adenosine A2A receptor ...

Japan-based Kyowa Kirin is fronting $330 million and pledging up to $1.1 billion in milestones to split the U.S. profits of Kura Oncology’s phase 2-stage oral leukemia treatment as well as to secure ...

Japanese drugmaker Kyowa Kirin has announced the discontinuation of all ongoing clinical trials for rocatinlimab, an investigational antiOX40 monoclonal antibody being evaluated for potential ...

"Partnering with Bioz has been a great experience," said Matthias Stiemer, Overseas Sales Department at Kyowa Interface Science. "We're already seeing excellent engagement from researchers exploring ...